Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Kinarus Therapeutics logo — Kinarus Therapeutics is a clinical-stage company developing...

Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocular diseases.

Founded 2017 Switzerland Basel, Switzerland 5 employees Post Ipo Equity Total: $36.55M Biopharma, Biotechnology +2

General Information

Company Name Kinarus Therapeutics
Founded Year 2017
Location Switzerland Basel, Switzerland +1
Employees 5
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post Ipo Equity
Social

Get notified when Kinarus Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage pharmaceutical company based in Switzerland. Established in 2017, the company is dedicated to developing innovative treatments for viral, respiratory, and ophthalmic diseases. Their flagship drug candidate is an oral combination of a P38 mitogen-activated protein kinase (p38 MAPK) inhibitor, acquired from Roche, and a second drug, designed to provide long-term effective treatment. Kinarus is currently conducting a significant Phase 2 clinical trial for hospitalized Covid-19 patients, aiming to reduce mortality and duration of hospital stay. The novel drug candidate addresses viral replication, inflammation, and organ damage. Additionally, they have secured regulatory approval for a one-year Phase 2 clinical trial for wet Age-Related Macular Degeneration, a condition often undertreated despite available therapies. Their innovative drug, administered alongside existing anti-VEGF agents, holds the potential to reduce injection frequency and offer enhanced therapeutic benefits. In terms of funding, Kinarus Therapeutics recently received a Fr.1.50M post-IPO equity investment on 11 May 2023 from Chaodian Culture, signifying continued investor confidence in the company's mission and potential. With a focus on critical healthcare needs and promising treatment approaches, Kinarus Therapeutics is a compelling player in the biopharma and biotechnology industries, positioning itself as a noteworthy venture for potential investors.

Taxonomy: clinical-stage pharmaceutical company, drug development, viral diseases, respiratory diseases, ophthalmic diseases, p38 MAPK inhibitor, Covid-19 treatment, Phase 2 clinical trial, Age-Related Macular Degeneration, VEGF inhibitors, regulatory approval, patient-focused treatments, Switzerland-based company, Roche collaboration, hospitalized patients

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1 •••• •••• 11 May 2023
Post-IPO Equity •••••• 1
Investor
22 Aug 2022
Grant •••••• - 13 Dec 2021
Series B •••••• - 01 Sep 2021
Convertible Note •••••• - 12 Aug 2018

View All 6 Funding Rounds

Kinarus Therapeutics Alternatives & Competitors

Kinarus Therapeutics vs
Antios Therapeutics
Antios Therapeutics United States

Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing therapies fo...

Unknown
1 employees
Biopharma, Biotechnology
Kinarus Therapeutics vs
Idenix Pharmaceuticals
Idenix Pharmaceuticals

Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a stron...

Post Ipo Equity
Biotechnology, Health Care
Kinarus Therapeutics vs
Prilenia
Prilenia United States

Dedicated to developing new treatments for neurodegenerative diseases and neurodevelopmental disorde...

Series B
57 employees
Biotechnology, Health Care

FAQ About Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocular diseases.
Kinarus Therapeutics was founded in 2017.
Kinarus Therapeutics is headquartered in Basel, Switzerland.
Kinarus Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care, Life Sciences.
Kinarus Therapeutics has approximately 5 employees.
Kinarus Therapeutics has completed 6 funding rounds, raising a total of $36.55M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Kinarus Therapeutics include Antios Therapeutics, Idenix Pharmaceuticals, Prilenia, Phenomix, Himuka AM Pharma / Himuka AM Australia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kinarus Therapeutics and Antios Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Kinarus Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy